|
| 36201707 | Reply to C. Marchetti et al. | J Clin Oncol | 2023 |
| 37858464 | Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. | Cell Rep | 2023 |
| 37752102 | Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. | Nat Commun | 2023 |
| 37795443 | The potential and challenges of targeting <i>MTAP</i>-negative cancers beyond synthetic lethality. | Front Oncol | 2023 |
| 37845213 | Molecular landscape and functional characterization of centrosome amplification in ovarian cancer. | Nat Commun | 2023 |
| 37577760 | PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. | EMBO J | 2023 |
| 37542936 | Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. | Eur J Cancer | 2023 |
| 37676655 | Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen-Reply. | JAMA Oncol | 2023 |
| 37220750 | Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes. | Cell Rep Med | 2023 |
| 37075255 | Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. | JCO Clin Cancer Inform | 2023 |
| 37072323 | Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. | Int J Gynecol Cancer | 2023 |
| 37474499 | The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. | Nat Commun | 2023 |
| 36801617 | Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10. | EBioMedicine | 2023 |
| 36672287 | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. | Cancers (Basel) | 2023 |
| 36928279 | Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35131874 | Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. | Mol Cancer Ther | 2022 |
| 35841803 | Response to the letter entitled "Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers". | ESMO Open | 2022 |
| 35398881 | The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. | Clin Cancer Res | 2022 |
| 35690073 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. | Lancet Oncol | 2022 |
| 35658487 | A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). | J Clin Oncol | 2022 |
| 35681688 | Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature. | Cancers (Basel) | 2022 |
| 36265336 | HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. | Cancer Treat Rev | 2022 |
| 36289203 | Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. | Nat Commun | 2022 |
| 35918200 | A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. | Gynecol Oncol | 2022 |
| 33414107 | Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. | Int J Gynecol Cancer | 2021 |
| 33907915 | The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia. | Inflammation | 2021 |
| 33570999 | FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. | JCO Clin Cancer Inform | 2021 |
| 33752918 | Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. | Gynecol Oncol | 2021 |
| 33551198 | Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448. | Gynecol Oncol | 2021 |
| 34893524 | Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. | J Immunother Cancer | 2021 |
| 34647981 | Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. | JAMA Oncol | 2021 |
| 34602290 | Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. | Gynecol Oncol | 2021 |
| 34452316 | Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. | Viruses | 2021 |
| 34564042 | The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. | Cancer Treat Rev | 2021 |
| 34478639 | Activating a collaborative innate-adaptive immune response to control metastasis. | Cancer Cell | 2021 |
| 34593565 | ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. | Int J Gynecol Cancer | 2021 |
| 33941851 | Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. | Oncogene | 2021 |
| 33941784 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). | Nat Commun | 2021 |
| 34016703 | Metronomic oral cyclophosphamide in relapsed ovarian cancer. | Int J Gynecol Cancer | 2021 |
| 34316715 | Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. | NAR Cancer | 2021 |
| 34289354 | Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. | Cell Rep | 2021 |
| 33032491 | Safe administration of chemotherapy in mast cell activation syndrome. | J Oncol Pharm Pract | 2021 |
| 33357510 | Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 32195317 | NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. | Mol Ther Oncolytics | 2020 |
| 31727629 | Prophylactic <i>In Vivo</i> Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models. | Cancer Res | 2020 |
| 32098980 | Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management. | Sci Rep | 2020 |
| 31940491 | Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. | Cell Rep | 2020 |
| 32919511 | Progression-free survival in the ICON8 trial - Authors' reply. | Lancet | 2020 |
| 32932156 | Organoid models in gynaecological oncology research. | Cancer Treat Rev | 2020 |
| 32615110 | Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. | Lancet Oncol | 2020 |